Langendijk H A, Lamers R J, ten Velde G P, Sanders D G, de Jong J M, Kessels F, Wouters E F
Radiotherapeutisch Instituut Limburg, Heerlen, The Netherlands.
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1037-45. doi: 10.1016/s0360-3016(98)00168-0.
The purpose of this study was to evaluate whether the chest radiograph is a reliable tool to assess response to radiotherapy.
Pre- and post-treatment chest radiographs and computed tomographs (CT) of 63 patients with nonsmall cell lung cancer (NSCLC) treated by radiotherapy were reviewed by four observers with regard to suitability for tumor measurement, and response. Suitability for tumor measurement was expressed as the number of measurable diameters. In addition, the consequences to clinical outcome were studied by survival analysis.
The CT turned out to be more suited for tumor measurement before as well as after radiotherapy, resulting in an increase of the number of measurable cases. The number of measurable cases with CT was 52 (83%) as compared to 28 (44%) with chest radiography. Especially in case of centrally localized tumors, the presence of an atelectasis, or squamous cell carcinoma, CT contributed to a higher rate of measurable cases. The interobserver agreement with regard to response using chest radiograph was good (mean kappa = 0.74). In 25 of 28 cases (89%) measurable with CT as well as with chest radiograph, response was equally classified. When CT was used, the median survival of the responders was 14.2 months as compared to 6.8 months of the nonresponders. When chest radiograph was used, the median survival of these groups was 12.0 and 6.6 months respectively, which was not significantly different when response was assessed by CT.
We conclude that CT is more suited for tumor measurement because more measurable lesions can be found and more evaluable lesions on chest radiograph become measurable on CT. The chest radiograph does have a valuable role to play in those lesions that are measurable because of the good interobserver agreement with regard to the response classification, the high overall agreement between CT and chest radiograph in case of measurable cases, and the lack of important differences with regard to survival.
本研究的目的是评估胸部X光片是否是评估放疗反应的可靠工具。
对63例接受放疗的非小细胞肺癌(NSCLC)患者治疗前和治疗后的胸部X光片及计算机断层扫描(CT)进行了回顾,由四名观察者评估其在肿瘤测量及反应方面的适用性。肿瘤测量的适用性以可测量直径的数量表示。此外,通过生存分析研究了其对临床结果的影响。
结果表明,CT在放疗前后均更适合肿瘤测量,可测量病例数量增加。CT的可测量病例数为52例(83%),而胸部X光片为28例(44%)。特别是对于中央型肿瘤、存在肺不张或鳞状细胞癌的情况,CT使得可测量病例的比例更高。观察者之间对于使用胸部X光片评估反应的一致性良好(平均kappa值 = 0.74)。在28例CT和胸部X光片均可测量的病例中,有25例(89%)反应分类相同。使用CT时,反应者的中位生存期为14.2个月,无反应者为6.8个月。使用胸部X光片时,这些组的中位生存期分别为12.0个月和6.6个月,通过CT评估反应时差异无统计学意义。
我们得出结论,CT更适合肿瘤测量,因为能发现更多可测量病变,且胸部X光片上更多可评估病变在CT上变为可测量。胸部X光片在那些可测量病变中确实具有重要作用,因为观察者之间对于反应分类的一致性良好,可测量病例中CT与胸部X光片的总体一致性较高,且在生存期方面无重要差异。